TPIDB > 臨床試驗主持人
臨床試驗主持人
更新時間：2025-03-06
徐志宏Hsu, Chih-Hung
- 計畫主持人
- 執行臨床試驗年資 23 年 9 個月
發表文獻
33筆
1
Zhu AX, Finn RS, Kang YK, Yen CJ, Galle PR, Llovet JM, Assenat E, Brandi G, Motomura K, Ohno I, Daniele B, Vogel A, Yamashita T, Hsu CH, Gerken G, Bilbruck J, Hsu Y, Liang K, Widau RC, Wang C, Abada P, Kudo M. Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. Br J Cancer. 2021 Apr;124(8):1388-1397. doi: 10.1038/s41416-021-01260-w. Epub 2021 Feb 3. PMID: 33531690; PMCID: PMC8039038.
2
Wu CH, Liang PC, Hsu CH, Chang FT, Shao YY, Ting-Fang Shih T. Total skeletal, psoas and rectus abdominis muscle mass as prognostic factors for patients with advanced hepatocellular carcinoma. J Formos Med Assoc. 2021 Jan;120(1 Pt 2):559-566. doi: 10.1016/j.jfma.2020.07.005. Epub 2020 Jul 8. PMID: 32651043.
3
Liu TH, Shao YY, Hsu CH. It takes two to tango: breakthrough advanced hepatocellular carcinoma treatment that combines anti-angiogenesis and immune checkpoint blockade. J Formos Med Assoc. 2021 Jan;120(1 Pt 1):1-4. doi: 10.1016/j.jfma.2020.07.009. Epub 2020 Jul 11. PMID: 32660891.
4
Shen YC, Yeh CP, Jeng YM, Hsu C, Hsu CH, Lin ZZ, Shao YY, Lu LC, Liu TH, Chen CH, Cheng AL. Limited Predictive or Prognostic Role of Tumor-Infiltrating Tissue-Resident Memory CD8 T Cells in Patients with Hepatocellular Carcinoma Receiving Immunotherapy. Cancers (Basel). 2021 Oct 14;13(20):5142. doi: 10.3390/cancers13205142. PMID: 34680292; PMCID: PMC8533865.
5
Chen BB, Lin ZZ, Shao YY, Hsu C, Hsu CH, Cheng AL, Liang PC, Shih TT. Early Changes in DCE-MRI Biomarkers May Predict Survival Outcomes in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: Two Prospective Phase II Trials. Cancers (Basel). 2021 Oct 1;13(19):4962. doi: 10.3390/cancers13194962. PMID: 34638446; PMCID: PMC8508238.
6
Chen BB, Shao YY, Lin ZZ, Hsu CH, Cheng AL, Hsu C, Liang PC, Shih TT. Dynamic Contrast-Enhanced and Intravoxel Incoherent Motion MRI Biomarkers Are Correlated to Survival Outcome in Advanced Hepatocellular Carcinoma. Diagnostics (Basel). 2021 Jul 26;11(8):1340. doi: 10.3390/diagnostics11081340. PMID: 34441274; PMCID: PMC8391260.
7
Guo JC, Lin CY, Lin CC, Huang TC, Lien MY, Lu LC, Kuo HY, Hsu CH. Response to Immune Checkpoint Inhibitors in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma May Be Affected by Tumor Sites. Oncology. 2021;99(10):652-658. doi: 10.1159/000517738. Epub 2021 Aug 2. PMID: 34340231.
8
Wang Y, Lu LC, Guan Y, Ho MC, Lu S, Spahn J, Hsu CH. Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance. Exp Hematol Oncol. 2021 Aug 16;10(1):45. doi: 10.1186/s40164-021-00237-y. PMID: 34399826; PMCID: PMC8365942.
9
Hung YP, Shao YY, Lee JM, Hsu C, Hsu CH, Yang MH, Chao Y. Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma. J Chin Med Assoc. 2021 Feb 1;84(2):144-150. doi: 10.1097/JCMA.0000000000000477. PMID: 33433132.
10
Shao YY, Sun NY, Jeng YM, Wu YM, Hsu C, Hsu CH, Hsu HC, Cheng AL, Lin ZZ. Eg5 as a Prognostic Biomarker and Potential Therapeutic Target for Hepatocellular Carcinoma. Cells. 2021 Jul 5;10(7):1698. doi: 10.3390/cells10071698. PMID: 34359867; PMCID: PMC8303881.
